Vepdegestrant for ESR1-mutated breast cancer is now FDA approved, offering a new biomarker-guided oral treatment for certain adults whose ER-positive, HER2-negative advanced or metastatic breast cancer has progressed after endocrine therapy.
On May 1, 2026, the US Food and Drug Administration approved vepdegestrant under the brand name Veppanu. The approval applies only when an ESR1 mutation has been identified using an FDA-authorized test and the cancer has progressed after at least one previous line of endocrine therapy [1,2]. (U.S. Food and Drug Administration)
This is an important development for patients whose breast cancer has become resistant to earlier hormone-based treatment. Vepdegestrant is not chemotherapy. It is an oral estrogen-receptor protein degrader designed to remove the receptor that helps many ER-positive breast cancer cells continue growing.
The approval does not mean that every patient with ER-positive breast cancer should receive vepdegestrant. ESR1 mutation testing is central to treatment selection because the clearest benefit in the VERITAC-2 trial was observed in the ESR1-mutated group, not across the entire study population [1,3].
Vepdegestrant FDA approval at a glance
| Treatment detail | What patients need to know |
|---|---|
| Generic and brand name | Vepdegestrant, sold in the United States as Veppanu |
| FDA approval date | May 1, 2026 |
| Approved cancer type | ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer |
| Previous treatment required | Disease progression after at least one line of endocrine therapy |
| Required biomarker | An ESR1 mutation detected through an FDA-authorized test |
| Companion diagnostic | Guardant360 CDx was approved to identify eligible patients through a blood-based test |
| Recommended dose | 200 mg by mouth once daily with food |
| Treatment duration | Continued until cancer progression or unacceptable toxicity |
| Important warning | QTc interval prolongation, which can affect heart rhythm |
| Treatment goal | To delay disease progression and potentially reduce measurable tumour burden; it is not established as a curative treatment |
The FDA simultaneously expanded the use of Guardant360 CDx as a companion diagnostic for detecting ESR1 mutations in patients who may benefit from vepdegestrant [4]. The test evaluates circulating tumour DNA in a blood sample, which may make biomarker assessment more accessible than another invasive tumour biopsy for some patients. (FDA Access Data)
Why the vepdegestrant approval matters
Approximately seven in ten breast cancers are driven, at least partly, by estrogen-receptor signalling. Endocrine medicines can control such cancers by reducing estrogen production, blocking the estrogen receptor or promoting receptor degradation.
However, an ER-positive breast cancer can change under the pressure of treatment. Alterations in the ESR1 gene are one recognised mechanism through which the estrogen receptor may remain active despite estrogen-depriving treatment. ESR1 mutations are uncommon in newly diagnosed, untreated primary breast cancer but are encountered more frequently in metastatic cancers previously exposed to endocrine therapy [3,6].
This is why an earlier endocrine medicine may initially work and later lose effectiveness. The tumour may still be ER-positive, but its biological behaviour may have changed.
Vepdegestrant provides a different way of targeting that altered biology. Instead of only competing with estrogen or lowering estrogen levels, it is designed to recruit the cell’s natural protein-disposal system and remove the estrogen receptor itself.
The approval also highlights a broader change in metastatic breast cancer treatment: a diagnosis such as “ER-positive, HER2-negative breast cancer” is no longer sufficient by itself to select every later-line treatment. ESR1, PIK3CA, AKT1, PTEN, BRCA and HER2-expression results can all influence treatment sequencing. Patients should therefore ask whether appropriate molecular testing has been performed whenever the disease progresses.
What is an ESR1 mutation?
ESR1 is the gene that provides instructions for producing estrogen receptor alpha. When estrogen binds to this receptor, it can activate signals that encourage an ER-positive breast cancer cell to grow and divide.
Certain ESR1 mutations alter the receptor so that it can remain active even when estrogen levels have been substantially reduced. This can reduce the effectiveness of treatments that depend mainly on depriving the tumour of estrogen, including aromatase inhibitors.
An ESR1 mutation is not inherited in most patients. It is usually a somatic alteration that develops within the cancer cells. Therefore, finding an ESR1 mutation in circulating tumour DNA does not automatically mean that children, siblings or other relatives have inherited the mutation.
The result should also not be confused with BRCA1 or BRCA2 testing. BRCA testing may identify inherited or acquired defects in DNA repair, whereas ESR1 testing evaluates an alteration connected to estrogen-receptor signalling and endocrine resistance.
How is ESR1 mutation testing performed?
The FDA-approved selection process for Veppanu is based on detecting an ESR1 mutation in plasma using an authorized test [2]. Guardant360 CDx is a blood-based next-generation sequencing test that analyses circulating tumour DNA released into the bloodstream by cancer cells [4]. (FDA Access Data)
A blood-based liquid biopsy has practical advantages. It does not require surgery, can examine DNA released from different cancer sites and may be repeated as the tumour evolves. However, the amount of tumour DNA in blood can vary. A negative blood result does not always answer every molecular question, particularly when little circulating tumour DNA is present. The oncology team may determine whether another blood test, archived tumour tissue or a new biopsy would provide useful information.
Patients should ask for the complete molecular report rather than relying only on a verbal statement that the test was “positive” or “negative.” The report should identify the mutation, specimen type, testing date and laboratory method.
How vepdegestrant works
Vepdegestrant is a heterobifunctional protein degrader, commonly described as a proteolysis-targeting chimera or PROTAC. One part of the molecule binds to the estrogen receptor, while another part binds to an E3 ligase called cereblon.
Bringing these two proteins together labels the estrogen receptor for disposal through the ubiquitin-proteasome system. The cancer cell then breaks down the receptor, reducing the amount of estrogen-receptor protein available to transmit growth signals [2]. Preclinical studies reported degradation of both wild-type and mutant estrogen receptors, although laboratory findings do not predict the response of every individual patient. (FDA Access Data)
This mechanism differs from conventional chemotherapy, which generally attacks rapidly dividing cells. Vepdegestrant is a targeted endocrine treatment, although targeted treatment can still cause clinically important side effects.
It also differs from fulvestrant. Fulvestrant is an injectable estrogen-receptor antagonist and degrader, while vepdegestrant is taken orally and uses targeted protein degradation to recruit the cell’s protein-removal machinery.
What did the VERITAC-2 trial show?
The FDA approval was based on VERITAC-2, an international phase 3 trial involving 624 adults with ER-positive, HER2-negative advanced or metastatic breast cancer. Of these participants, 270 had an ESR1 mutation.
All trial participants had experienced progression after one or two endocrine therapy lines, including treatment with a CDK4/6 inhibitor. Participants were randomly assigned to receive oral vepdegestrant or intramuscular fulvestrant [1,3,5]. (U.S. Food and Drug Administration)
Key VERITAC-2 results
| Trial outcome | Vepdegestrant | Fulvestrant | What the result means |
|---|---|---|---|
| Median progression-free survival in ESR1-mutated patients | 5.0 months | 2.1 months | Vepdegestrant reduced the relative risk of progression or death by approximately 43% |
| Hazard ratio in the FDA analysis | 0.57 | Reference group | Statistically significant benefit in the ESR1-mutated population |
| Objective response rate in ESR1-mutated patients | 19% | 4% | Measurable tumour shrinkage occurred more often with vepdegestrant |
| Median progression-free survival in the entire trial population | 3.8 months | 3.6 months | The difference was not statistically significant |
| Overall survival | Immature | Immature | It is too early to determine whether vepdegestrant extends overall survival |
In the ESR1-mutated population, median progression-free survival was five months with vepdegestrant and 2.1 months with fulvestrant. The FDA reported a hazard ratio of 0.57, indicating an approximately 43% relative reduction in the risk of disease progression or death during the analysis period. The objective response rate was 19% with vepdegestrant compared with 4% with fulvestrant [1]. (U.S. Food and Drug Administration)
The overall trial population produced a different result. Among all 624 participants, including those without an ESR1 mutation, median progression-free survival was 3.8 months with vepdegestrant and 3.6 months with fulvestrant. That difference did not reach statistical significance [3]. (PubMed)
This distinction is clinically important. Vepdegestrant should not be portrayed as equally effective for all ER-positive, HER2-negative breast cancers. The approval is specifically tied to the presence of an ESR1 mutation.
What does “median progression-free survival of five months” mean?
A median progression-free survival of five months does not mean that vepdegestrant works for exactly five months in every patient.
It means that, at the time used for the analysis, half of the patients had experienced progression or death before five months and half remained progression-free beyond five months. Some patients may progress earlier, while others may maintain control substantially longer.
The hazard ratio provides a broader comparison across the follow-up period. A hazard ratio of 0.57 represents a relative reduction in the risk of progression or death compared with fulvestrant. It does not mean that 43% of patients were cured, nor does it guarantee tumour shrinkage in an individual patient.
The objective response rate of 19% means that approximately one in five evaluable ESR1-mutated patients experienced enough measurable tumour reduction to meet the trial’s response criteria. Other patients may have experienced stable disease without meeting the threshold for a partial response.
Overall survival data were still immature when the FDA made its decision. It is therefore not yet possible to conclude that vepdegestrant helps patients live longer than fulvestrant [1].
Who may be eligible for vepdegestrant?
A patient may be considered for vepdegestrant when all the main elements of the FDA indication are present: the patient is an adult; the breast cancer is ER-positive and HER2-negative; the disease is advanced or metastatic; an ESR1 mutation is confirmed using an FDA-authorized test; and progression has occurred after at least one endocrine therapy line [1,2].
The approval applies to adults and is not limited exclusively to women. A man with breast cancer may therefore be considered when the biological and previous-treatment criteria are satisfied.
The FDA label does not state that a previous CDK4/6 inhibitor is an absolute eligibility requirement. However, every VERITAC-2 participant had previously received a CDK4/6 inhibitor with endocrine therapy. This means that the strongest direct clinical evidence comes from the post-CDK4/6 treatment setting.
Vepdegestrant is not currently FDA approved for early-stage breast cancer, for preventing recurrence after surgery or for ESR1-negative disease. Its use outside the approved indication would require a separate clinical judgement or clinical-trial setting.
Treatment selection must also consider the location and speed of progression, symptoms, previous medicines, organ function, other actionable mutations and whether the patient needs a treatment capable of producing a faster response.
How is Veppanu taken?
The recommended vepdegestrant dose is 200 mg by mouth once daily with food. Treatment continues until the cancer progresses or side effects become unacceptable [1,2].
The tablet should be swallowed whole. It should not be chewed, crushed, dissolved or split. A tablet that is cracked, broken or visibly damaged should not be taken.
When a dose is missed or the patient vomits after taking it, the FDA instructions advise taking the next dose at the regularly scheduled time rather than taking an additional replacement dose [2]. (FDA Access Data)
When toxicity requires a reduction, the prescribing information provides for a reduction to 100 mg once daily. Patients should never reduce, increase or interrupt the dose without instructions from their oncology team.
Taking the medicine at approximately the same time each day and associating it with a regular meal may support adherence. A written medicine diary can also help record doses, symptoms, other medicines and laboratory appointments.
What are the common vepdegestrant side effects?
The most frequently reported clinical side effects included musculoskeletal pain in 30% of treated patients, fatigue in 29%, nausea in 14%, reduced appetite in 11%, constipation in 10% and ECG-detected QT prolongation in 10%.
Frequently observed laboratory abnormalities included reduced white blood cells, haemoglobin, neutrophils and platelets, along with changes in AST, ALT, alkaline phosphatase, bilirubin and potassium [2]. (FDA Access Data)
Serious adverse reactions occurred in 9% of patients receiving vepdegestrant. Treatment was permanently discontinued because of an adverse reaction in 2.9%, interrupted in 14% and dose-reduced in 1.9% [2]. These figures indicate that many patients were able to continue treatment, but they should not be used to minimise the need for monitoring. (FDA Access Data)
Musculoskeletal pain may involve the muscles, joints, bones, neck, back or limbs. New pain should not automatically be assumed to be a medicine side effect because bone metastases, fractures, electrolyte disturbances and other conditions can produce similar symptoms.
Nausea, appetite loss and constipation can gradually affect calorie intake, hydration, muscle mass and treatment tolerance. Reporting these symptoms early allows the treatment team to investigate the cause and introduce appropriate supportive measures before the patient becomes significantly weaker.
Heart-rhythm monitoring is particularly important
Vepdegestrant can prolong the QTc interval, an electrical measurement related to the heart’s recovery between beats. Significant prolongation can increase the risk of a dangerous abnormal rhythm.
The prescribing information recommends correcting low potassium or magnesium before and during treatment, performing an ECG before treatment, and not initiating vepdegestrant when the QTc interval exceeds 470 milliseconds. An ECG should generally be repeated approximately four weeks after starting treatment and later when clinically indicated [2]. (FDA Access Data)
Patients with heart failure, congenital long-QT syndrome, previous rhythm problems, electrolyte disturbances or medicines that can prolong QT may need additional monitoring.
Fainting, a racing or irregular heartbeat, severe dizziness, sudden weakness, chest discomfort or an unexplained loss of consciousness requires prompt medical assessment. Patients should not wait for their routine appointment when potentially serious cardiac symptoms appear.
Drug, food and herbal interactions
Vepdegestrant is affected by CYP3A, an enzyme involved in the processing of many prescription medicines, over-the-counter products and herbs. Strong CYP3A inhibitors can raise vepdegestrant exposure and potentially increase toxicity, while strong CYP3A inducers may lower exposure and reduce treatment effectiveness [2].
The medicine can also affect certain P-glycoprotein and UGT1A9 substrates. Medicines with their own QT-prolonging potential require particular caution because combining them with vepdegestrant may further increase cardiac risk. (FDA Access Data)
The FDA patient information specifically advises avoiding grapefruit, grapefruit juice and St John’s wort during treatment. Patients should give their oncologist and oncology pharmacist a complete list of prescription drugs, supplements, vitamins, herbal powders, teas, extracts and Ayurvedic formulations [2]. (FDA Access Data)
A product being natural does not guarantee that it is interaction-free. Even a familiar herb can affect drug-metabolising enzymes, electrolytes, blood pressure, sedation, bleeding or liver function. This is especially relevant when the patient has liver metastases, raised bilirubin, reduced kidney function or a previous heart-rhythm abnormality.
Pregnancy, contraception and breastfeeding
Vepdegestrant can cause fetal harm based on its mechanism and animal findings. Females who can become pregnant and males with female partners who can become pregnant should use effective contraception throughout treatment and for two weeks after the final dose [2].
Breastfeeding is not recommended during treatment or for two weeks after the last dose. Vepdegestrant may also impair fertility in males or females of reproductive potential. Fertility preservation should therefore be discussed before treatment when this is personally relevant. (FDA Access Data)
Is vepdegestrant a cure for metastatic breast cancer?
Vepdegestrant should not be presented as a proven cure for metastatic breast cancer. Its approval is based on improved progression-free survival and a higher response rate in the ESR1-mutated population. Overall survival results remain immature.
Nevertheless, delaying progression can be meaningful. Additional months of disease control may preserve organ function, relieve or prevent symptoms, postpone the need for another treatment and provide time for further therapeutic options to become available.
Individual outcomes vary considerably. A patient’s response may be influenced by the number and location of metastases, tumour burden, previous endocrine sensitivity, coexisting genetic changes, overall health and the cancer’s rate of progression.
The effectiveness of treatment should be assessed objectively through symptoms, physical examination, laboratory results, appropriate tumour markers and scheduled imaging. Feeling better is valuable, but it should not replace scans when determining whether metastatic disease is responding.
What the approval means for patients outside the United States
FDA approval is a United States regulatory decision. It does not automatically establish authorization, reimbursement or commercial availability in the United Kingdom, Canada, Australia or Singapore.
Patients in these countries should ask their oncologist whether vepdegestrant has received local authorization, whether an access programme is available and whether the necessary ESR1 testing can be performed through an accredited laboratory. Regulatory and reimbursement decisions can occur at different times, so availability may differ between countries and even between treatment centres.
A patient should not obtain the medicine through an unverified online source. Oncology medicines require confirmed diagnosis, authentic supply, interaction screening, ECG assessment, laboratory monitoring and a structured response-evaluation plan.
How Ayurveda may support patients receiving vepdegestrant
Ayurveda may be most useful in this setting when it is practised as coordinated, patient-specific supportive care rather than as an unmonitored replacement for oncology treatment.
Vepdegestrant targets a defined molecular driver inside the cancer cell. Ayurveda takes a broader whole-person approach involving nutrition, daily routine, sleep, movement, digestive function, mental well-being and individualized preparations. These approaches can be complementary when their purposes are clearly understood and safety is actively managed.
A recovery-oriented Ayurvedic plan may focus on maintaining appetite, digestion, bowel regularity, hydration, sleep, emotional stability and physical strength. It may also address fatigue, musculoskeletal discomfort, treatment-related weakness and the progressive loss of muscle mass that can make continued cancer treatment more difficult.
This wider support can matter because treatment success is not determined only by the tablet. A patient must also remain sufficiently nourished, functional and medically stable to continue treatment, attend monitoring appointments and receive the next appropriate therapy when required.
A small, single-arm study involving 32 breast cancer survivors evaluated a four-month individualized Ayurvedic programme incorporating nutrition, lifestyle guidance, yoga and marma. The intervention was feasible and acceptable, with signals of improvement in sleep, fatigue, emotional functioning and quality of life. However, the participants had previously treated stage I–III disease and no active cancer, so this study does not prove tumour control in metastatic breast cancer [7]. (Sage Journals)
A separate prospective but non-randomized study of 100 breast cancer patients receiving chemotherapy found lower fatigue scores and improvements in some quality-of-life measures among patients who also received Withania somnifera. The study was not conducted with vepdegestrant, was not randomized and cannot establish an anticancer or survival benefit [8]. (Sage Journals)
The available research therefore supports careful investigation of Ayurveda for symptom burden and quality of life, but it does not establish that an Ayurvedic formulation eliminates an ESR1 mutation or cures metastatic breast cancer. The most responsible healing strategy is to combine realistic goals with objective monitoring rather than forcing patients to choose between medical systems.
Patients seeking a personalized, recovery-focused integrative plan can read about Ayurvedic support for breast cancer. Such care should be designed around the patient’s cancer subtype, metastatic sites, current medicines, digestive tolerance, constitution, blood counts, liver and kidney results, nutritional status and treatment-related symptoms.
Safety rules for combining Ayurveda with vepdegestrant
No Ayurvedic herb, mineral preparation, concentrated extract or supplement should be started blindly during vepdegestrant treatment.
The full formula, dose, manufacturer and laboratory testing details should be disclosed to the oncology team. This is particularly important because vepdegestrant is affected by CYP3A and can prolong the QT interval. A formulation that alters CYP3A activity, potassium, magnesium, liver enzymes or cardiac rhythm could theoretically change treatment safety or effectiveness.
The US National Center for Complementary and Integrative Health notes that relatively few well-designed clinical trials have evaluated Ayurveda for most medical conditions. It also warns that some Ayurvedic products have contained potentially toxic amounts of lead, mercury or arsenic [6]. (NCCIH)
Products used during cancer treatment should therefore come from a traceable source with batch-specific testing for identity, microbial contamination, pesticides and heavy metals. “Traditional,” “natural” or “herbal” should never be treated as a substitute for quality control.
The oncologist should remain informed even when the Ayurvedic programme mainly involves food and lifestyle. Patients with low white-cell counts may need additional food-safety precautions, while those with liver dysfunction, kidney impairment, bowel obstruction, pleural effusion, ascites or significant weight loss require specialized nutritional planning.
Building a coordinated recovery plan
A practical integrative plan begins with a shared treatment objective. This may be disease control, reduction in measurable lesions, relief from pain, preservation of liver or lung function, improvement in appetite, restoration of sleep or maintenance of body weight and muscle strength.
The oncology component should define the cancer-directed treatment, scan schedule, laboratory monitoring and criteria for continuing or changing vepdegestrant.
The Ayurvedic component can then be individualized around digestion, nutritional tolerance, bowel habits, sleep, pain, fatigue, daily routine and emotional strain without interfering with the cancer medicine. Gentle movement, breathing exercises, appropriately planned food and restorative routines may be valuable, but they must be adapted for bone metastases, anaemia, breathlessness, infection risk and physical weakness.
Progress should be measured rather than assumed. A patient diary can record daily food intake, weight, pain, bowel movements, sleep, activity, medicine adherence and new symptoms. These observations complement rather than replace blood tests and imaging.
The safest and most convincing integrative approach is transparent: the patient knows which intervention is targeting the tumour, which intervention is supporting recovery and how both will be monitored.
Questions to ask the oncologist
Before beginning treatment, a patient should ask whether the latest tumour or blood test confirms an ESR1 mutation; whether the cancer remains ER-positive and HER2-negative; why vepdegestrant is preferred over another endocrine medicine, targeted drug, antibody–drug conjugate or chemotherapy; and when the first response scan will be performed.
It is also important to ask which blood tests and ECG monitoring are required, which medicines or supplements could interact, what symptoms require an urgent call, and what the next treatment option would be if vepdegestrant does not control the cancer.
Patients using complementary medicine should bring the actual containers, ingredient lists or prescriptions to the consultation rather than stating only that they take “some herbs.” Exact information makes a meaningful interaction review possible.
Frequently asked questions
Is vepdegestrant chemotherapy?
No. Vepdegestrant is an oral targeted endocrine treatment and protein degrader. It is designed to remove the estrogen receptor that supports the growth of ER-positive breast cancer cells.
What is the brand name for vepdegestrant?
The FDA-approved US brand name is Veppanu.
Does every patient need an ESR1 test before taking it?
Under the FDA-approved indication, an ESR1 mutation must be detected using an FDA-authorized test. Guardant360 CDx has been approved as a companion diagnostic for this purpose.
Can an ESR1-negative patient take vepdegestrant?
The present FDA indication is limited to ESR1-mutated disease. In VERITAC-2, vepdegestrant did not produce a statistically significant progression-free survival advantage in the full population, which included ESR1-negative patients.
Is vepdegestrant approved for early-stage breast cancer?
No. The current approval is for eligible adults with advanced or metastatic ER-positive, HER2-negative, ESR1-mutated breast cancer after progression on at least one endocrine therapy line.
Is vepdegestrant more effective than fulvestrant?
In patients with an ESR1 mutation, vepdegestrant produced longer median progression-free survival and a higher objective response rate than fulvestrant. A statistically significant advantage was not demonstrated in the complete study population.
Can male breast cancer patients receive vepdegestrant?
The FDA indication applies to adults rather than women only. Men may be considered when their cancer and previous-treatment history meet the approved criteria.
Can vepdegestrant be taken with Ayurvedic medicine?
Potentially, but only after a complete interaction and safety review. Vepdegestrant is affected by CYP3A and can prolong the QT interval. Every herbal, mineral and nutritional product should be disclosed to the oncologist and pharmacist before use.
How soon will doctors know whether it is working?
The monitoring schedule is individualized. The oncology team will usually assess symptoms and laboratory results between visits and perform imaging at a planned interval based on the disease burden, clinical condition and treatment protocol.
Does tumour shrinkage mean the cancer is cured?
No. Tumour shrinkage is a treatment response, but it does not by itself establish cure. Continued monitoring is necessary because microscopic or measurable disease may remain.
The bottom line
The FDA approval of vepdegestrant marks an important advance for adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer that has progressed after endocrine therapy.
Its strongest evidence is in patients with a confirmed ESR1 mutation. In this group, vepdegestrant extended median progression-free survival from 2.1 months with fulvestrant to five months and increased the objective response rate from 4% to 19% [1,3].
The treatment is oral, biomarker-directed and scientifically innovative, but it is not free from risk. ECG monitoring, electrolyte correction, laboratory assessment and a careful review of prescription medicines, foods and supplements are essential.
Ayurveda may add value through a personalized programme directed toward nutrition, digestion, sleep, strength, fatigue, pain, emotional stability and treatment tolerance. Its safest role is coordinated supportive care that helps create stronger conditions for recovery while scans, laboratory results and oncology assessments continue to measure the cancer itself.
This article is for patient education and does not replace diagnosis, prescribing or treatment decisions from a qualified oncology team.
References
[1] US Food and Drug Administration. FDA approves vepdegestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer. Published May 1, 2026. Used for the approved indication, trial population, progression-free survival, response rate, warnings and dosage.
[2] US Food and Drug Administration. Veppanu (vepdegestrant) Prescribing Information. Used for patient selection, dosage, administration, mechanism, adverse reactions, QT monitoring, pregnancy precautions and drug interactions.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219835Orig1s000lbl.pdf
[3] Campone M, et al. Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer. New England Journal of Medicine. Used for the peer-reviewed VERITAC-2 design and efficacy results in the ESR1-mutated and overall populations.
https://pubmed.ncbi.nlm.nih.gov/40454645
[4] US Food and Drug Administration. Guardant360 CDx Premarket Approval Supplement P200010/S025. Used for the companion diagnostic indication for detecting ESR1 mutations in patients being considered for Veppanu.
https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?ID=P200010S025
[5] ClinicalTrials.gov. VERITAC-2: Study of vepdegestrant compared with fulvestrant in adults with ER-positive, HER2-negative advanced breast cancer. Used for trial registration and study-design information.
https://clinicaltrials.gov/study/NCT05654623
[6] Jeselsohn R, et al. ESR1 mutations as a mechanism for acquired endocrine resistance in breast cancer. Used for the biological relationship between ESR1 mutations and resistance to endocrine therapy.
https://pubmed.ncbi.nlm.nih.gov/26122181
[7] National Center for Complementary and Integrative Health. Ayurvedic Medicine: In Depth. Used for the description of Ayurveda, limitations of the current evidence, product-safety concerns and the need for coordinated care.
https://www.nccih.nih.gov/health/ayurvedic-medicine-in-depth
[8] Dhruva A, et al. A 4-Month Whole-Systems Ayurvedic Medicine Nutrition and Lifestyle Intervention Is Feasible and Acceptable for Breast Cancer Survivors. Used for preliminary evidence relating to quality of life, sleep, fatigue and emotional well-being.
https://pubmed.ncbi.nlm.nih.gov/33312762
[9] Biswal BM, et al. Effect of Withania somnifera on the Development of Chemotherapy-Induced Fatigue and Quality of Life in Breast Cancer Patients. Used for preliminary supportive-care evidence and its methodological limitations.
